{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:18:56Z","timestamp":1773328736824,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jdiacomp.2022.108286","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T23:31:38Z","timestamp":1660779098000},"page":"108286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes"],"prefix":"10.1016","volume":"36","author":[{"given":"Eleni","family":"Pappa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Kostara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Bairaktari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Arvaniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilis","family":"Tsimihodimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2022.108286_bb0005","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease.The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0015","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0020","first-page":"187","article-title":"Pharmacological management of diabetic dyslipidemia","volume":"10","author":"Filippatos","year":"2017","journal-title":"Expert RevClinPharmacol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/1566524053766086","article-title":"Type 2 diabetes as a lipid disorder","volume":"5","author":"Taskinen","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0035","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00125-011-2444-6","article-title":"Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes","volume":"55","author":"Stahlman","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0040","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verges","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/1570161115666170201105425","article-title":"Pathophysiology of diabetic dyslipidaemia","volume":"15","author":"Filippatos","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/157016111796642661","article-title":"\"European panel on low density lipoprotein (LDL) subclasses\": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses","volume":"9","author":"Mikhailidis","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0055","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0060","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.2174\/0929867326666190201142321","article-title":"Cardioprotective properties of HDL: structural and functional considerations","volume":"27","author":"Pappa","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0065","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.atherosclerosis.2016.06.044","article-title":"HDL metrics, let's call the number thing off?","volume":"251","author":"Sposito","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0070","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1194\/jlr.M100431-JLR200","article-title":"LDL and HDL enriched in triglyceride promote abnormal cholesterol transport","volume":"43","author":"Skeggs","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0075","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1172\/JCI5286","article-title":"Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men","volume":"103","author":"Lamarche","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agerso","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0085","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2174\/0929867324666170414164244","article-title":"Incretins and lipid metabolism","volume":"25","author":"Tsimihodimos","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehu264","article-title":"HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative","volume":"36","author":"Martin","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.numecd.2014.06.010","article-title":"Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight\/obese persons with prediabetes","volume":"24","author":"Ariel","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0105","first-page":"32","article-title":"Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis","volume":"25","author":"Verges","year":"1999","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.8.2.168","article-title":"Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes","volume":"8","author":"Taskinen","year":"1988","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2337\/diab.33.4.333","article-title":"In vivo stimulation of low-density lipoprotein degradation by insulin","volume":"33","author":"Mazzone","year":"1984","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0120","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1463-1326.2011.01423.x","article-title":"Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes","volume":"13","author":"Chaudhuri","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1742-1241.2012.02972.x","article-title":"Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome","volume":"66","author":"Agouridis","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0130","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1373\/clinchem.2005.058404","article-title":"Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma","volume":"51","author":"Gazi","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can J Biochem Physiol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0140","series-title":"Methodologies for Metabolomics: Experimental Strategies And Techniques","first-page":"317","article-title":"Lipid profiling in health and disease","author":"Kostara","year":"2013"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0145","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/acs.jproteome.6b00975","article-title":"NMR-based lipid profiling of high density lipoprotein particles in healthy subjects with low, normal, and elevated HDL-cholesterol","volume":"16","author":"Kostara","year":"2017","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228835","article-title":"Early signs of atherogenic features in the HDL lipidomes of normolipidemic patients newly diagnosed with type 2 diabetes","volume":"21","author":"Kostara","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0155","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1021\/acs.jproteome.9b00227","article-title":"Evaluation of multivariate classification models for analyzing NMR metabolomics data","volume":"18","author":"Vu","year":"2019","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0160","first-page":"92","article-title":"Multivariate analysis in metabolomics","volume":"1","author":"Worley","year":"2013","journal-title":"Curr Metabol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0165","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/cem.1187","article-title":"CV-ANOVA for significance testing of PLS and OPLS\u00ae models","volume":"22","author":"Eriksson","year":"2008","journal-title":"J Chemometr"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0170","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.phrs.2018.09.003","article-title":"Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort","volume":"137","author":"Mirani","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/dia.2016.0405","article-title":"A fixed ratio combination of Insulin Degludec and Liraglutide (IDegLira) reduces glycemic fluctuation and brings more patients with type 2 diabetes within blood glucose target ranges","volume":"19","author":"King","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0190","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/304032","article-title":"Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide","volume":"2014","author":"Voukali","year":"2014","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.07.007","article-title":"Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial","volume":"288","author":"Anholm","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0210","first-page":"7967380","article-title":"Correlation between cholesterol, triglycerides, calculated, and measured lipoproteins: whether calculated small density lipoprotein fraction predicts cardiovascular risks","volume":"2017","author":"Khan","year":"2017","journal-title":"JLipids"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0215","doi-asserted-by":"crossref","first-page":"26910","DOI":"10.1074\/jbc.270.45.26910","article-title":"Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability","volume":"270","author":"Sparks","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0220","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2337\/diacare.28.8.1965","article-title":"Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study","volume":"28","author":"Selvin","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/diab.30.9.773","article-title":"Effect of the membrane lipid environment on the properties of insulin receptors","volume":"30","author":"Ginsberg","year":"1981","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0230","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/ATVBAHA.107.145672","article-title":"Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities","volume":"27","author":"Kontush","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","article-title":"Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities","volume":"21","author":"Kontush","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1194\/jlr.M300231-JLR200","article-title":"In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux","volume":"45","author":"Yancey","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0245","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0022-2275(20)31525-X","article-title":"Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL","volume":"42","author":"de La Llera-Moya","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0250","doi-asserted-by":"crossref","first-page":"12538","DOI":"10.1021\/bi025998k","article-title":"Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling","volume":"41","author":"Rye","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0255","doi-asserted-by":"crossref","first-page":"7716","DOI":"10.3390\/ijms14047716","article-title":"Sphingomyelin in high-density lipoproteins: structural role and biological function","volume":"14","author":"Martinez-Beamonte","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2009.05.029","article-title":"Metabolism and atherogenic disease association of lysophosphatidylcholine","volume":"208","author":"Schmitz","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MOL.0b013e32834d2dc5","article-title":"Recent insights into the relation of Delta5 desaturase and Delta6 desaturase activity to the development of type 2 diabetes","volume":"23","author":"Kroger","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jdiacomp.2022.108286_bb0270","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-019-0954-6","article-title":"Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway","volume":"18","author":"Wu","year":"2019","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:15:40Z","timestamp":1761005740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872722001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1056872722001982"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108286","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108286"}}